Evaluation criteria According to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guideline, the efficacy Criteria are: complete Response (CR): All the target lesions disappeared completely; Partial response (PR): the sum of diameters of all measurable target lesions was ≥ 30% below baseline; Stable disease (SD): the total diameter of lesions at baseline has a decreasing trend but does not meet the standard of PR, or it has increased but does not meet the evaluation standard of progressive disease (PD); PD: The total diameter of the target lesions increases by 20% over baseline or new lesions appear.
← all excerpts
Effect of pembrolizumab on T lymphocyte subsets in patients with advanced oral cancer and its therapeutic effect.
1
—
—